Omvoh (Mirikizumab-mrkz) Injection shortage
Possibly permanent — Eli Lilly, the only company we could find that sells mirikizumab-mrkz injections, has told the FDA it is discontinuing its product as of Oct 8, 2026. The FDA lists this under “To be discontinued”. We could not find another company that sells the same medicine, so talk with your prescriber about a long-term plan before your supply runs out.
Eli Lilly is permanently discontinuing Omvoh (mirikizumab-mrkz) 100 mg/1 mL injection, with distribution ending April 2026. The 200 mg/2 mL presentation of Omvoh will remain available as a replacement.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this medicine? See the ‘What to do’ note from Dr. Brian Staiger, PharmD →Is Omvoh still in shortage? — status as of Oct 8, 2026
Still listed as “To be discontinued” as of Oct 8, 2026. We could not find another company that sells mirikizumab-mrkz injections, so this may become permanent. Talk with your prescriber about a long-term plan before your supply runs out.
The charts count only the companies that reported this shortage to the FDA; companies that haven’t reported a problem are in the green card, and the Supply-Risk rating counts them too.
Shortage timeline
-
Dec 22, 2025Currently in shortage2 of 2 products affected.
-
Dec 22, 2025First reported to the FDA2 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
Which Omvoh products are affected — by company
Company: Eli Lilly and Co. 📞 800-545-5979 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Omvoh Injection, 100 mg/mL | 100 mg/mL | — | A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-1442-11) will remain. | — |
| To Be Discontinued | Omvoh Injection, 100 mg/mL | 100 mg/mL | — | A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-3116-11) will remain. | — |
These rows are company reports to the FDA for Mirikizumab-mrkz Injection — they do not cover every company that lists this medicine. A company appears here only if it told the FDA it has a supply problem, so other companies may still have stock. That’s the basis for the Where else can I get Omvoh or its generic? options further down this page.
Why is Eli Lilly discontinuing Omvoh?
Eli Lilly has made a business decision to permanently stop distributing two specific package versions of Omvoh (mirikizumab-mrkz) — both are the 100 mg/1 mL injection presentations. Distribution of these packages will end in April 2026. No further reason beyond it being a business decision was shared publicly.
The good news is that Eli Lilly has confirmed that the 200 mg/2 mL injection version of Omvoh will continue to be available — so the drug itself is not going away entirely, just these particular package sizes.
Based on the company-reported reason(s) and notes on file with the FDA for Mirikizumab-mrkz Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as companies report changes.
What should I do if I take Omvoh?
Mirikizumab-mrkz injection — sold as Omvoh — is currently on the FDA shortage list, and I want to walk you through what that means for you.
The affected product is the 100 mg/1 mL injection. Right now, this strength has no reported available source. According to the manufacturer, Eli Lilly, this is a business decision to discontinue the 100 mg/1 mL presentation, with distribution ending in April 2026. Because this is a planned discontinuation rather than a temporary supply gap, the shortage of this specific strength may be permanent. Lilly also notes that the 200 mg/2 mL injection presentation is expected to remain available.
Please do not stop, skip, or change your doses on your own. Since your strength is being discontinued, the right next step is a conversation with the person who prescribes it.
Here is how I'd approach this:
- Talk with your prescriber or pharmacist soon about your options — for example, a clinician-chosen way to continue treatment or a different presentation of the same medicine.
- The same medicine (mirikizumab, 100 mg/mL) is listed from Eli Lilly, so your pharmacy may be able to check wholesalers for current stock, though it may not be on hand locally.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually make these calls. This is general, national information and may not reflect your local pharmacy's actual stock.
- Ask your pharmacy to check other companies’ versions, other strengths, package sizes, and nearby stores — the options below are a starting point.
- If this is part of an ongoing or essential regimen (for example HIV, seizure, heart, transplant, diabetes or mental-health medicines), arrange continued supply before you run out rather than rationing doses.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Omvoh or its generic?
FDA shortages are company-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every company that lists mirikizumab-mrkz injections is necessarily short. Below are the other listings in the current FDA NDC Directory that are not reported in shortage: the same medicine from companies that haven’t reported a problem (the reporting company is excluded), and other dosage forms. These are generic versions of Omvoh — a switch from the brand goes through your pharmacist or prescriber. Some listings are repackagers, which relabel another company’s product. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Other dosage forms of mirikizumab-mrkz
A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:
Therapeutic equivalents & pricing 4 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Omvoh 100 mg/mL | Eli | 2 syringes | — | — | FDA listed |
| Omvoh 100 mg/mL | Eli | 2 syringes | — | — | FDA listed |
| Omvoh 100 mg/mL | Eli | 1 syringe | — | — | FDA listed |
| Omvoh 100 mg/mL | Eli | 1 syringe | — | — | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Omvoh — that fall in the same broad treatment class (interleukin-23 (il-23) receptor antagonist) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Codes & classification for pharmacists and billers
Where does this data come from?
Omvoh shortage FAQs
Is Omvoh still in shortage?
Which strengths of Omvoh are affected?
Which Omvoh products are affected?
When will Omvoh be available again?
Can I still get Omvoh or its generic somewhere?
Is the brand or the generic affected?
What should I do if I take Omvoh?
Still have a question about the Omvoh shortage?
Ask a pharmacist about this shortage →View Mirikizumab-Mrkz Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (companies listing the same ingredient & form — the "other companies" the rating counts); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.